Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Non Operating Income: 2022-2025

Historic Non Operating Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to $2.0 million.

  • ARS Pharmaceuticals' Non Operating Income fell 22.10% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 3.23%. This contributed to the annual value of $11.4 million for FY2024, which is 13.58% down from last year.
  • Per ARS Pharmaceuticals' latest filing, its Non Operating Income stood at $2.0 million for Q3 2025, which was down 25.27% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Non Operating Income ranged from a high of $3.8 million in Q1 2023 and a low of -$151,000 during Q1 2022.
  • For the 3-year period, ARS Pharmaceuticals' Non Operating Income averaged around $3.0 million, with its median value being $3.0 million (2024).
  • Per our database at Business Quant, ARS Pharmaceuticals' Non Operating Income skyrocketed by 6,521.28% in 2023 and then decreased by 22.71% in 2024.
  • Quarterly analysis of 4 years shows ARS Pharmaceuticals' Non Operating Income stood at $1.2 million in 2022, then skyrocketed by 164.99% to $3.1 million in 2023, then decreased by 1.08% to $3.0 million in 2024, then decreased by 22.10% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.7 million for Q2 2025, and $3.2 million during Q1 2025.